作者
Matthew J. Lennon,Darren M. Lipnicki,Ben C. P. Lam,John D. Crawford,Aletta E. Schutte,Ruth Peters,Therese Rydberg Sterner,Jenna Najar,Ingmar Skoog,Steffi G. Riedel‐Heller,Susanne Röhr,Alexander Pabst,António Lobo,Concepción De‐la‐Cámara,Elena Lobo,Richard B. Lipton,Mindy J. Katz,Carol A. Derby,Ki Woong Kim,Ji Won Han,Dae Jong Oh,E Rolandi,Annalisa Davin,Michele Rossi,Nikolaos Scarmeas,Mary Yannakoulia,Themis Dardiotis,Hugh C. Hendrie,Sujuan Gao,Isabelle Carrière,Karen Ritchie,Kaarin J. Anstey,Nicolas Cherbuin,Shifu Xiao,Ling Yue,Wei Li,Maëlenn Guerchet,Pierre‐Marie Preux,Victor Aboyans,Mary N. Haan,Allison E. Aiello,Márcia Scazufca,Perminder S. Sachdev
摘要
Previous randomized controlled trials and longitudinal studies have indicated that ongoing antihypertensive use in late life reduces all-cause dementia risk, but the specific impact on Alzheimer dementia (AD) and non-AD risk remains unclear. This study investigates whether previous hypertension or antihypertensive use modifies AD or non-AD risk in late life and the ideal blood pressure (BP) for risk reduction in a diverse consortium of cohort studies.